NitroMed Hopes To Reach 35% Tier II Formulary Coverage For BiDil By End Of March
This article was originally published in The Pink Sheet Daily
Executive Summary
Tier II reimbursement is “critical” to success of the dual vasodilator for African-Americans with heart failure, company says.